1. Pink Sheet

Breaking Down the First “Breakthrough”

 
• By Michael McCaughan

Vertex’ cystic fibrosis research is the recipient of the first two “Breakthrough” designations issued by FDA. That underscores the likelihood that the primary value of the new pathway will be as a badge for investors. And that’s probably a good thing.

Now we know. About two months after FDA disclosed that it had awarded the first "Breakthrough" therapy designation under the FDA Safety & Innovation Act, the designee finally identified itself: Vertex Pharmaceuticals Inc.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet